stockrow
Saturday 7 November 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
9.54
0.17
+1.81%
Follow SNDX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | — | — |
+8 more TTM periods Free account |
| (426.43%) | (255.93%) | (189.53%) | (161.82%) | ||
| (33.67%) | (33.97%) | (43.70%) | (45.50%) | ||
ROIC |
(83.42%) | (247.93%) | (573.79%) | 0.00% | |
Return on Tangible Assets |
(46.90%) | (38.36%) | (63.15%) | (69.93%) | |
Average Days of Receivables |
96.75 | 101.57 | 98.98 | 144.31 | |
Free Cash Flow per Share |
(1.98) | (2.48) | (3.15) | (3.73) | |
Free Cash Flow |
(177.59) | (220.87) | (278.16) | (322.94) | |
Capital Expenditures |
(0.23) | (0.23) | — | 0.04 | |
| Other line items | |||||
Cash ROIC |
(17.61%) | (19.08%) | (37.25%) | (39.28%) | |
Accounts Receivable Turnover |
4.91 | 4.78 | 5.55 | 4.34 | |
Accounts Payable Turnover |
2.59 | 0.96 | 0.83 | 0.49 | |
Inventory Turnover |
0.70 | 0.42 | 0.44 | 0.42 | |
Average Days of Payables |
57.85 | 167.09 | 453.97 | 868.25 | |
Days of Inventory on Hand |
637.55 | 1,136.93 | 1,463.18 | 1,715.24 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
94.32% | 103.89% | 117.87% | 150.15% | |
Selling, General and Administrative Expense of Revenue |
59.69% | 69.04% | 81.15% | 104.25% | |
Share Based Compensation of Revenue |
18.18% | 19.60% | 22.64% | 27.56% | |
Interest Coverage |
(3.69) | (4.45) | (5.75) | (7.79) | |
Operating CF/Net income |
0.85 | 1.00 | 1.14 | 1.13 | |
Depreciation/Fixed assets |
(20.09) | (23.94) | (44.77) | (58.12) | |
Capex/Depreciation |
0.05 | 0.04 | 0.00 | 0.00 | |
Revenue per Share |
3.22 | 2.83 | 2.46 | 1.99 | |
Operating CF per Share |
(1.98) | (2.48) | (3.15) | (3.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026